Adoptive transfer of alloanergized donor T cells is a simple approach to augment immune reconstitution while limiting GvHD after TCD haploidentical (haplo) HSCT. However the optimal dose and impact on antigen-specific immune reconstitution remain unknown. On a new study, 7 adults and 4 children received fractionated TBI (12Gy, n 5 5) or melphalan (140mg/m 2 , n 5 6), fludarabine, thiotepa and ATG followed by CD34-selected peripheral blood stem cells (median 9.4 CD34 1 and 0.02 CD3 1 Â10 6 cells/kg) from haplo donors without further GvHD prophylaxis. All engrafted rapidly with full donor chimerism. Using an adaptive trial design, 10 pts received alloanergized donor PBMC (generated by co-culture with irradiated stimulator PBMC and humanized anti-B7.1 and -B7.2 antibodies resulting in a median 6-fold reduction in alloresponses) in escalating dose (Ds) cohorts: Ds1, 10 3 CD3 1 cells/kg (n 5 4), Ds2 10 4 /kg (n 5 3) and Ds3 10 5 /kg (n 5 3). 3 pts developed Gr 2-4 acute GvHD, (1 Ds 2, 2 Ds3), all responding to treatment. 0/7 evaluable pts developed chronic GvHD. 7/11 pts are alive (median f/u 8 months). 3 pts died from regimen related toxicity before D1100 and 1 from post-operative bleeding (D1738). 2 pts relapsed. CD4 T cell recovery was faster and functional pathogen-specific CD4 and CD8 T cells became detectable earlier in pts receiving higher doses of alloanergized PBMC. Median time to CD4 ct .100/ml was 9, 3 and 2 months and CMV or VZV-specific IFN-g 1 T cells became detectable at 7.5, 3 and 2.5 months at Ds 1,2 and 3 respectively. The effector memory phenotype of recovering T cells was consistent with peripheral expansion of infused alloanergized donor T cells. 5 pts reactivated CMV before alloanergized PBMC infusion, but no new episodes of CMV reactivation or CMV disease occurred after infusion. 2 pts had large expansions of CMV-specific CD4 and CD8 T cells (up to 10%) before D1100, coinciding with clearance of CMV viremia. One Ds3 pt had adenoviremia despite high dose cidofovir, resolving with expansion of infused donor T cells. 2 Ds1 pts developed late viral infections: 1 reactivated EBV, and 1 developed disseminated VZV resolving after VZV-specific T cells became detectable. No late viral infections occurred in assessable Ds2/3 pts. These early data support a contribution of alloanergized donor PBMC to quantitative and qualitative immune reconstitution after TCD haploHSCT. Further recruitment will determine the optimal dose that can be safely administered in this setting.
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RAPID LYMPHOCYTE RECOVERY AND INTRAVENOUS IMMUNOGLOBU-LIN INDEPENDENCE IN CHILDREN WITH SEVERE COMBINED IMMUNO-DEFICIENCY (SCID) UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION WITH REDUCED INTENSITY CONDITIONING (RIC)
Guarino, J.A., Kletzel, M., Schneiderman, J., Jacobsohn, D., Chaudhury, S., Duerst, R., Tse, W. Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL Allogeneic SCT is curative for patients with SCID. We evaluated a RIC SCT approach in these patients for engraftment, toxicity and immune reconstitution. Between 2000 and 2008, RIC transplant was performed in 14 SCID patients (8 males and 6 females; median age 5 months (range 1.1-98.3)). Median time from diagnosis to transplant was 1.8 months (range 1.0-96.3). Donor sources included: HLAmatched related donor peripheral blood stem cells (PBSC) (n 5 1), unrelated donor PBSC (7), related cord blood (CB) (1) and unrelated CB (6). The median cell dose was 10.3 Â 10 8 TNC/kg and 9.2 Â 10 6 CD341cells/kg, and 2.0 Â 10 8 TNC/kg and 1.5 Â 10 6 CD341cells/kg for the PBSC and CB groups, respectively. RIC regimen included Fludarabine 30mg/m 2 /day, days -10 through -5, intravenous Busulfan targeted to AUC 4000-5000 microMol*min/day, days -5 and -4, and anti-thymocyte globulin 2mg/kg/day, days -4 through -1. GVHD prophylaxis included cyclosporine A and mycophenolate mofetil. Engraftment occurred in 8/8 (100%) PBSC recipients and 4/6 (67%) CB recipients. Absolute neutrophil count (ANC) .1000 was achieved at a median of 17 days (range 4-26) and platelets .50K was achieved at a median of 23 days (12-90). The ANC never dropped \500 for 8/14 (57%), and platelets never dropped \20K for 8/14 (57%) patients. Full donor chimerism (VNTR $ 95%) was achieved by a median of 26 days in 11/14 patients (79%; 8 received PBSC, 3 received CB). Stable mixed donor chimerism (VNTR $ 50%) was achieved by 74 days for 1 patient who received CB. Two patients who received CB doses of 1.19/1.99 Â 10 8 TNC/kg, and 0.69/0.55 Â 10 6 CD341cells/kg, respectively, experienced graft failure and died from complications. The other patients tolerated the transplant with mild toxicities. No VOD or grade III/IV acute or chronic GVHD was seen. Infections seen post-transplant (bacterial (n 5 9), candidemia (1), and viral (8)) responded to antimicrobial therapy except in 1 graft failure patient. Immune reconstitution studies performed post-transplant showed rapid recovery of various lymphocyte subsets (table) . Normal endogenous IgG levels were achieved by day 1180 and patients no longer required IV immunoglobulin. The 100-day transplant mortality was 14.3%. The Kaplan-Meier estimate of overall survival at 2 years was 80% (95% CI 47.5-90%). This RIC SCT protocol is a novel, non-toxic approach that allows for adequate donor engraftment with early immune reconstitution and correction of the underlying immunodeficiency in children with SCID.
Immune Reconstitution Post-RIC SCT * Results were compared to a group of pediatric patients (n 5 13) with leukemia conditioned with the same RIC and grafted with a CD341 selected PBSC from unrelated donors. There were not differences in T and B lymphocyte recovery between groups. However, a significantly difference was observed in the NK cell reconstitution. NK Poster Session-II
